GOAT; Phase I Single-Center Open Label Dose Escalation Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Therapy of Advanced Cancers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2013
At a glance
- Drugs ONCOS 102 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms GOAT
- 13 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 20 Jun 2013 Planned initiation date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 03 Dec 2012 Planned End Date changed from 1 Nov 2021 to 1 Dec 2021 as reported by ClinicalTrials.gov.